What does this research mean for the field?

Intravesical immunotherapies demonstrate superior efficacy, response durability, and safety profiles compared to systemic checkpoint inhibitors in treating bladder cancer, supporting their prioritization in BCG-unresponsive non-muscle-invasive disease. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the efficacy and safety of emerging immunotherapies for bladder cancer.

June 10, 2026BMC UrologyOpen Access

Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances

View Full Paper

Ask AI

Bookmark

Authors

AAAhmed Alasker MAMohammad AlGhafees TNTalah Nammor

Discussion

Member takes

Overview

Systematic review reveals intravesical therapies show superior efficacy in bladder cancer, suggesting a shift in treatment strategies.

Key Points

The aim is to evaluate the efficacy and safety of emerging immunotherapies for bladder cancer.
Conducted systematic review of phase 2 and 3 trials from PubMed, Cochrane, Web of Science, and Scopus.
Evaluated intravesical and systemic immunotherapies for non-muscle-invasive and muscle-invasive bladder cancer.
Performed risk-of-bias assessments using Cochrane tool and synthesized results qualitatively.
Intravesical Cretostimogene Grenadenorepvec had the highest complete response rate of 75.2% with a durable response at 83%.
Nadofaragene Firadenovec showed complete response of 53.4% with a median duration of 9.69 months.
Systemic Pembrolizumab had a 12-month disease-free survival of 43.5%, but raised concerns with 14% reporting grade ≥ 3 adverse events.

Cite This Study

Alasker et al. (2026) studied this question.

synapsesocial.com/papers/6a28fe9f6f82f25be989bd47 https://doi.org/10.1186/s12894-026-02209-y

View Full Paper

Ask AI

Bookmark

June 10, 2026BMC UrologyOpen Access

Immunotherapy in bladder cancer: a systematic review of clinical trials and therapeutic advances

View Full Paper

Ask AI

Bookmark

Authors

AAAhmed Alasker MAMohammad AlGhafees TNTalah Nammor

Discussion

Member takes

Overview

Systematic review reveals intravesical therapies show superior efficacy in bladder cancer, suggesting a shift in treatment strategies.

Key Points

The aim is to evaluate the efficacy and safety of emerging immunotherapies for bladder cancer.
Conducted systematic review of phase 2 and 3 trials from PubMed, Cochrane, Web of Science, and Scopus.
Evaluated intravesical and systemic immunotherapies for non-muscle-invasive and muscle-invasive bladder cancer.
Performed risk-of-bias assessments using Cochrane tool and synthesized results qualitatively.
Intravesical Cretostimogene Grenadenorepvec had the highest complete response rate of 75.2% with a durable response at 83%.
Nadofaragene Firadenovec showed complete response of 53.4% with a median duration of 9.69 months.
Systemic Pembrolizumab had a 12-month disease-free survival of 43.5%, but raised concerns with 14% reporting grade ≥ 3 adverse events.

Cite This Study

Alasker et al. (2026) studied this question.

synapsesocial.com/papers/6a28fe9f6f82f25be989bd47 https://doi.org/10.1186/s12894-026-02209-y

View Full Paper

Ask AI

Bookmark